Overview
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Description
PRIMARY OBJECTIVE:
I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and have their medical records reviewed on study.
Eligibility
Inclusion Criteria:
- 18 years of age or older
- Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
- One of the following:
- Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
- Completed chemotherapy with no cardiotoxicity at least two years post treatment
- Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
- An understanding of the protocol and its requirements, risks, and discomforts
- The ability and willingness to sign an informed consent
Exclusion Criteria:
\- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
